Study S001881

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)

Registration

Registration: NCT06143956
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: RECRUITING
Enrollment: 1481
Start: 2023-11-17
Primary completion: 2027-09
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:LY3305677; DRUG:LY3841136; DRUG:Tirzepatide; DRUG:LY3549492; DRUG:LY3532226; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:W8M-MC-CWMM; OTHER:W8M-MC-OXA1; OTHER:W8M-MC-LAA1; OTHER:W8M-MC-LAA2; OTHER:W8M-MC-GN01; OTHER:W8M-MC-GN02; OTHER:W8M-MC-MC01

Registered primary outcomes

Number of Participants Allocated to Each ISA [Baseline to Week 6]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.